Colorado Sues Alvogen Over Oxycodone Without Diversion Monitoring

Colorado Attorney General Phil Weiser's office filed a lawsuit on Oct. 15 accusing Alvogen, Inc., a New Jersey pharmaceutical company, of selling large quantities of generic oxycodone since 2012 without the internal monitoring system federal law requires of drug manufacturers. The five-page complaint, filed in Denver District Court, alleges the company's conduct violated the Colorado Consumer Protection Act and seeks a consent judgment rather than a trial. Weiser, who has been attorney general since 2019, says his office has secured $912 million in opioid settlement funds from similar cases in that time.

What the complaint says was missing

The lawsuit centers on a control that rarely appears in public debate about the opioid supply: the suspicious order monitoring system, known in regulatory shorthand as an SOM. Federal law and Drug Enforcement Administration regulations require manufacturers to run an algorithm that tracks the pharmacies and wholesalers buying their drugs, flagging unusual purchase frequency, order sizes, and volumes that do not match the documented need for prescription painkillers in a given region.

The purpose is diversion detection — catching the pharmacy that suddenly orders ten times its usual volume before those pills reach a street market. According to the attorney general's office, Alvogen never had an effective system of that kind in place, leaving it without anti-diversion controls for pills it manufactured and shipped for well over a decade. Westword reported that the complaint describes the omission as a violation of Colorado's consumer protection statute rather than as a criminal matter.

A short complaint with a single developed theory

The filing runs five pages, and one of its two theories is far more detailed than the other. The monitoring claim is spelled out: a specific federal requirement, a specific absence, and a specific state law the absence is said to violate. The second theory — that Alvogen misrepresented the health risks and benefits of opioids — appears in the complaint without the particulars that would normally accompany it.

That imbalance is worth noting because the misrepresentation claim is the part of opioid litigation that generally produces the largest damages figures, and the part that takes the most discovery to prove out. On the current record, the case Colorado has actually built is about internal controls and record-keeping obligations, not about sales messaging. The attorney general's office reaches back to the mid-1990s push by pharmaceutical companies to expand prescribing, then points forward to the addictions that followed, but the complaint does not tie that history to specific Alvogen conduct.

The overdose numbers behind the filing

The complaint arrives with Denver's own death data attached to the public conversation around it. The Denver Department of Public Health & Environment recorded 563 drug overdose deaths inside the city in 2025, 405 of them involving opioids — including fentanyl, the synthetic that dominates the current illicit supply. Roughly 63 percent of the city's overdose cases involved someone who was not experiencing homelessness, a detail that cuts against the assumption that the toll is concentrated in one population.

Nationally, the Centers for Disease Control and Prevention counted about 105,000 drug overdose deaths in 2023, with nearly 80,000 — roughly 76 percent — involving opioids. Colorado's own experience has run against the national trend in recent years, which is the backdrop for a slogan-free question in the complaint: what obligations did a generic manufacturer owe a state whose death rate was climbing while its pills were moving through it. People seeking care for an established prescription opioid dependence can find detoxification, medication and counseling through opioid treatment programs.

A consent judgment, not a trial

The remedy the state asks for is itself a signal about where the case is heading. Colorado does not request a specific dollar figure. It asks the court to enter a consent judgment, an instrument that typically reflects a negotiated settlement reached before the complaint is filed and finalized once a judge approves it. If that is how this ends, Alvogen would be the latest in a line of manufacturers that resolved Colorado's claims without a trial.

The state's accumulated opioid litigation proceeds are large enough that Colorado built a public accounting system for them: researchers at the University of Colorado Anschutz Medical Campus launched a settlement spending dashboard that tracks how the money is being used regionally. The attorney general's office announced a $12 million grant round for prevention, treatment, recovery and peer support programs statewide in July.

What the filing does not say

Weiser's statement to Westword framed the case as a hedge against federal retreat. He said the federal government is working to cut opioid treatment and prevention funding through health program reductions and proposed rollbacks at the Substance Abuse and Mental Health Services Administration, and that collecting from manufacturers matters more when public dollars are contracting. "I will continue to hold accountable drugmakers like Alvogen and any other companies that knowingly pushed addictive products and fueled the opioid and addiction crisis," he said.

What the complaint does not supply is the size of the state's ask, the volume of oxycodone the company is alleged to have shipped into Colorado, or any accounting of how many of those pills are claimed to have been diverted. Those numbers would have to come from discovery — or from the consent judgment, if one arrives.